Simulations Plus Partners with Three Pharma Companies to Advance AI Workflows
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 26 2026
0mins
Should l Buy SLP?
Simulations Plus announced strategic collaboration programs with three large pharmaceutical companies to advance artificial intelligence workflows across the drug development lifecycle. These programs apply AI within scientifically grounded modeling workflows and define how next-generation workflows are deployed at scale. The close collaboration between Simulations Plus and leading pharmaceutical organizations will provide direct insight into how AI will be integrated into real-world environments-informing product direction, workflow standardization, and future commercial models. The programs will utilize Simulations Plus' major software platforms, including GastroPlus, MonolixSuite, ADMET Predictor, and Thales. Participating companies will integrate the Company's internally developed AI agents directly into model-informed drug development workflows, enabling natural language interaction, automation of data processing, coordination of simulations across multiple modeling engines, and generation of interpretable outputs from complex, multi-step pipelines.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SLP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SLP
Wall Street analysts forecast SLP stock price to rise
5 Analyst Rating
2 Buy
3 Hold
0 Sell
Moderate Buy
Current: 11.960
Low
19.00
Averages
19.00
High
19.00
Current: 11.960
Low
19.00
Averages
19.00
High
19.00
About SLP
Simulations Plus, Inc. is a provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. It operates through two segments: software and services. The Company’s business units include cheminformatics, physiologically based pharmacokinetics, clinical pharmacology and pharmacometrics, quantitative systems pharmacology, adaptive learning & insights and medical communications. The Company operates in biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry. It delivers simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development. Its cutting-edge technology is licensed and utilized by pharmaceutical, biotechnology, and regulatory agencies worldwide.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Simulations Plus Schedules Q2 2026 Earnings Call
- Earnings Report Announcement: Simulations Plus will release its Q2 fiscal 2026 financial results after market close on April 9, 2026, reflecting the company's ongoing innovation in drug development.
- Conference Call Timing: Management will host a conference call at 5:00 p.m. Eastern Time on the same day to discuss the financial results with investment professionals and current and prospective shareholders, enhancing transparency and communication.
- Participation Options: Investors can join the call by dialing 1-877-451-6152 for domestic or 201-389-0879 for international access, or by registering through a provided link to ensure timely information dissemination.
- Replay Availability: The webcast will be available for replay approximately one hour after the call on the Simulations Plus investor relations page, further improving interaction and information sharing between the company and its investors.
See More
Rosen Law Firm Investigates Simulations Plus for Misleading Information
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Simulations Plus (NASDAQ: SLP) for possibly issuing misleading business information, indicating potential legal liabilities for the company.
- Performance Miss: Simulations Plus reported third-quarter 2025 sales of $20.4 million, a 10% year-over-year increase, but fell short of the consensus estimate of $20.9 million, undermining investor confidence.
- Stock Price Plunge: Following the disappointing earnings report on July 15, 2025, Simulations Plus' stock plummeted by 25.75%, reflecting market concerns about the company's future outlook.
- Class Action Preparation: Rosen Law Firm is preparing a class action lawsuit, allowing investors to seek compensation without any out-of-pocket fees, demonstrating the firm's commitment to protecting investor rights.
See More
Simulations Plus Extends Collaborations with FDA and NIEHS
- FDA Collaboration Extension: Simulations Plus has extended its agreement with the FDA to further develop and refine AI models for chemical safety assessments of food-related substances, leveraging new federal funding to enhance access to toxicological datasets for improved model training and validation.
- NIEHS Research Expansion: The collaboration with NIEHS focuses on environmental and exposure-related chemical safety research, addressing a broad range of chemicals and exposure scenarios, aligning with NIEHS's mission to support human health research and modernize chemical safety assessments through AI-driven methodologies.
- Advancing NAM Research: The extension reflects ongoing federal interest in computational and AI-based approaches, where Simulations Plus has 30 years of technical expertise, contributing to the scientific foundation for drug development and food safety research.
- Industry Leadership: Simulations Plus accelerates the discovery, development, and commercialization of pharmaceuticals and other products through innovative science-based software and consulting solutions, further solidifying its leadership position in biopharma innovation.
See More
Simulations Plus Extends Collaborations with FDA and NIEHS
- FDA Collaboration Extension: Simulations Plus has extended its agreement with the FDA's Human Foods Program to continue utilizing computational models for chemical safety assessments of food-related substances, leveraging new federal funding to further expand the application of AI safety models and enhance regulatory research effectiveness.
- NIEHS Research Expansion: The collaboration with NIEHS will focus on environmental and exposure-related chemical safety research, addressing a wide range of chemicals and exposure scenarios, aligning with NIEHS's mission to support research on environmental influences on human health and modernizing chemical safety assessments.
- Advancing NAM Research: The extension of these collaborations reflects ongoing federal interest in computational and AI-based approaches, where Simulations Plus has longstanding technical expertise, committed to advancing the scientific foundation for drug development and food safety research.
- Industry Leadership: Over the past 30 years, Simulations Plus has laid the scientific groundwork for model-informed drug development, with standardized methods widely accepted by industry and regulators, continuing to pioneer the science and technology that support better-informed decision-making.
See More
Rosen Law Firm Investigates Simulations Plus Securities Claims
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Simulations Plus (NASDAQ:SLP) for allegedly issuing materially misleading business information, indicating significant transparency issues within the company.
- Stock Price Plunge: On July 15, 2025, Simulations Plus' stock plummeted by 25.75% following the release of its third-quarter earnings report, reflecting a substantial decline in market confidence regarding the company's future performance, which could damage investor trust.
- Poor Financial Performance: Simulations Plus reported sales of $20.4 million, a 10% year-over-year increase, yet it fell short of the consensus estimate of $20.9 million, highlighting ongoing weakness in market demand that may affect future investment appeal.
- Class Action Preparation: Rosen Law Firm is preparing a class action for affected investors, promising compensation without upfront costs, indicating that the company faces legal risks that could further impact shareholder value.
See More
Rosen Law Firm Investigates Securities Claims for Simulations Plus Shareholders
- Securities Claims Investigation: The Rosen Law Firm is investigating potential securities claims against Simulations Plus (NASDAQ: SLP) due to allegations of misleading business information, highlighting serious concerns about the company's transparency and accountability to investors.
- Performance Misses Expectations: Simulations Plus reported third-quarter sales of $20.4 million in 2025, a 10% year-over-year increase, but fell short of the consensus estimate of $20.9 million, indicating persistent demand weakness and declining market confidence.
- Significant Stock Drop: Following the disappointing earnings report on July 15, 2025, Simulations Plus's stock plummeted by 25.75%, resulting in substantial financial losses for investors and exacerbating concerns about the company's future performance.
- Class Action Preparation: The Rosen Law Firm is preparing a class action lawsuit against Simulations Plus, allowing investors to participate in claims without upfront costs, demonstrating the firm's strong commitment to protecting investor rights and seeking recovery for losses.
See More
Simulations Plus Schedules Q2 2026 Earnings Call
- Earnings Report Announcement: Simulations Plus will release its Q2 fiscal 2026 financial results after market close on April 9, 2026, reflecting the company's ongoing innovation in drug development.
- Conference Call Timing: Management will host a conference call at 5:00 p.m. Eastern Time on the same day to discuss the financial results with investment professionals and current and prospective shareholders, enhancing transparency and communication.
- Participation Options: Investors can join the call by dialing 1-877-451-6152 for domestic or 201-389-0879 for international access, or by registering through a provided link to ensure timely information dissemination.
- Replay Availability: The webcast will be available for replay approximately one hour after the call on the Simulations Plus investor relations page, further improving interaction and information sharing between the company and its investors.
See More
Rosen Law Firm Investigates Simulations Plus for Misleading Information
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Simulations Plus (NASDAQ: SLP) for possibly issuing misleading business information, indicating potential legal liabilities for the company.
- Performance Miss: Simulations Plus reported third-quarter 2025 sales of $20.4 million, a 10% year-over-year increase, but fell short of the consensus estimate of $20.9 million, undermining investor confidence.
- Stock Price Plunge: Following the disappointing earnings report on July 15, 2025, Simulations Plus' stock plummeted by 25.75%, reflecting market concerns about the company's future outlook.
- Class Action Preparation: Rosen Law Firm is preparing a class action lawsuit, allowing investors to seek compensation without any out-of-pocket fees, demonstrating the firm's commitment to protecting investor rights.
See More
Simulations Plus Extends Collaborations with FDA and NIEHS
- FDA Collaboration Extension: Simulations Plus has extended its agreement with the FDA to further develop and refine AI models for chemical safety assessments of food-related substances, leveraging new federal funding to enhance access to toxicological datasets for improved model training and validation.
- NIEHS Research Expansion: The collaboration with NIEHS focuses on environmental and exposure-related chemical safety research, addressing a broad range of chemicals and exposure scenarios, aligning with NIEHS's mission to support human health research and modernize chemical safety assessments through AI-driven methodologies.
- Advancing NAM Research: The extension reflects ongoing federal interest in computational and AI-based approaches, where Simulations Plus has 30 years of technical expertise, contributing to the scientific foundation for drug development and food safety research.
- Industry Leadership: Simulations Plus accelerates the discovery, development, and commercialization of pharmaceuticals and other products through innovative science-based software and consulting solutions, further solidifying its leadership position in biopharma innovation.
See More
Simulations Plus Extends Collaborations with FDA and NIEHS
- FDA Collaboration Extension: Simulations Plus has extended its agreement with the FDA's Human Foods Program to continue utilizing computational models for chemical safety assessments of food-related substances, leveraging new federal funding to further expand the application of AI safety models and enhance regulatory research effectiveness.
- NIEHS Research Expansion: The collaboration with NIEHS will focus on environmental and exposure-related chemical safety research, addressing a wide range of chemicals and exposure scenarios, aligning with NIEHS's mission to support research on environmental influences on human health and modernizing chemical safety assessments.
- Advancing NAM Research: The extension of these collaborations reflects ongoing federal interest in computational and AI-based approaches, where Simulations Plus has longstanding technical expertise, committed to advancing the scientific foundation for drug development and food safety research.
- Industry Leadership: Over the past 30 years, Simulations Plus has laid the scientific groundwork for model-informed drug development, with standardized methods widely accepted by industry and regulators, continuing to pioneer the science and technology that support better-informed decision-making.
See More
Rosen Law Firm Investigates Simulations Plus Securities Claims
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Simulations Plus (NASDAQ:SLP) for allegedly issuing materially misleading business information, indicating significant transparency issues within the company.
- Stock Price Plunge: On July 15, 2025, Simulations Plus' stock plummeted by 25.75% following the release of its third-quarter earnings report, reflecting a substantial decline in market confidence regarding the company's future performance, which could damage investor trust.
- Poor Financial Performance: Simulations Plus reported sales of $20.4 million, a 10% year-over-year increase, yet it fell short of the consensus estimate of $20.9 million, highlighting ongoing weakness in market demand that may affect future investment appeal.
- Class Action Preparation: Rosen Law Firm is preparing a class action for affected investors, promising compensation without upfront costs, indicating that the company faces legal risks that could further impact shareholder value.
See More
Rosen Law Firm Investigates Securities Claims for Simulations Plus Shareholders
- Securities Claims Investigation: The Rosen Law Firm is investigating potential securities claims against Simulations Plus (NASDAQ: SLP) due to allegations of misleading business information, highlighting serious concerns about the company's transparency and accountability to investors.
- Performance Misses Expectations: Simulations Plus reported third-quarter sales of $20.4 million in 2025, a 10% year-over-year increase, but fell short of the consensus estimate of $20.9 million, indicating persistent demand weakness and declining market confidence.
- Significant Stock Drop: Following the disappointing earnings report on July 15, 2025, Simulations Plus's stock plummeted by 25.75%, resulting in substantial financial losses for investors and exacerbating concerns about the company's future performance.
- Class Action Preparation: The Rosen Law Firm is preparing a class action lawsuit against Simulations Plus, allowing investors to participate in claims without upfront costs, demonstrating the firm's strong commitment to protecting investor rights and seeking recovery for losses.
See More
